Harpreet Grewal - Penumbra Independent Director
| PEN Stock | USD 280.38 0.95 0.34% |
Director
Mr. Harpreet S. Grewal is the Independent Director of the Company. Mr. Grewal has served on the Board since April 2015. Since August 2017, Mr. Grewal was an advisor to a number of technology companies. From February 2016 through April 2017, Mr. Grewal served as General Manager of Constant Contact, Inc., a technology company primarily focused on marketing tools and a whollyowned indirect subsidiary of Endurance International Group Holdings, Inc. . Prior to the acquisition of Constant Contact by Endurance, from 2010 to February 2016, Mr. Grewal served as Executive Vice President and Chief Financial Officer of Constant Contact. From 2008 to 2009, Mr. Grewal worked as an independent consultant to small businesses and earlystage entrepreneurs. From 2006 through 2008, Mr. Grewal was Executive Vice President and Chief Financial Officer of VistaPrint, Ltd., a publiclytraded online printing and marketing services company. Prior to VistaPrint, Mr. Grewal was Senior Vice President and Chief Financial Officer of GoldenSource Corporationrationration, a data management company, from 2002 to 2006, Chief Financial Officer of eGain Communications Corporationrationration, a customer engagement services company, from 1999 to 2002, and held various financial and strategic planning positions with PepsiCo, Inc., a publiclytraded food and beverage company, from 1996 to 1999 since 2015.
| Age | 53 |
| Tenure | 10 years |
| Address | One Penumbra Place, Alameda, CA, United States, 94502 |
| Phone | 510 748 3200 |
| Web | https://www.penumbrainc.com |
Latest Insider Transactions
Grewal received a B.A. from the University of California, Berkeley and a M.A. from Johns Hopkins University.Harpreet Grewal Latest Insider Activity
Tracking and analyzing the buying and selling activities of Harpreet Grewal against Penumbra stock is an integral part of due diligence when investing in Penumbra. Harpreet Grewal insider activity provides valuable insight into whether Penumbra is net buyers or sellers over its current business cycle. Note, Penumbra insiders must abide by specific rules, including filing SEC forms every time they buy or sell Penumbra'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Harpreet Grewal over two months ago Disposition of 167 shares by Harpreet Grewal of Penumbra at 241.28 subject to Rule 16b-3 |
Penumbra Management Efficiency
The company has Return on Asset of 0.0484 % which means that on every $100 spent on assets, it made $0.0484 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.012 %, implying that it generated $0.012 on every 100 dollars invested. Penumbra's management efficiency ratios could be used to measure how well Penumbra manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Equity is likely to grow to 0.01, while Return On Tangible Assets are likely to drop 0.01. At this time, Penumbra's Non Current Assets Total are very stable compared to the past year. As of the 22nd of March 2025, Non Currrent Assets Other is likely to grow to about 148.3 M, while Total Assets are likely to drop about 820.4 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Workman | CONMED | 69 | |
| David Bronson | CONMED | 67 | |
| Alvin Jeffers | Integer Holdings Corp | 47 | |
| Shawn McCormick | Inspire Medical Systems | 56 | |
| Jerry Griffin | Inspire Medical Systems | 76 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Michelle Brennan | Masimo | 58 | |
| Dana Mead | Inspire Medical Systems | 61 | |
| William Summers | Integer Holdings Corp | 70 | |
| Jerome Lande | CONMED | 45 | |
| Charles Farkas | CONMED | 68 | |
| Shelley Broader | Inspire Medical Systems | 56 | |
| Brian Concannon | CONMED | 62 | |
| Jean Hobby | Integer Holdings Corp | 60 | |
| Martha Aronson | CONMED | 53 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| Georgia GarinoisMelenikiotou | Inspire Medical Systems | 60 | |
| Stephanie Zhadkevich | iRhythm Technologies | N/A | |
| Megan CPA | Inspire Medical Systems | N/A | |
| Kristen CFA | Integer Holdings Corp | N/A | |
| Filippo Passerini | Integer Holdings Corp | 63 | |
Management Performance
| Return On Equity | 0.012 | ||||
| Return On Asset | 0.0484 |
Penumbra Leadership Team
Elected by the shareholders, the Penumbra's board of directors comprises two types of representatives: Penumbra inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Penumbra. The board's role is to monitor Penumbra's management team and ensure that shareholders' interests are well served. Penumbra's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Penumbra's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ben Tompkins, Executive Development | ||
| Surbhi Sarna, Independent Director | ||
| Bridget ORourke, Independent Director | ||
| Adam Elsesser, Chairman of the Board, Chief Executive Officer | ||
| James Pray, President International | ||
| Shruthi Narayan, Executive Interventional | ||
| Gita Barry, President Healthcare | ||
| Holly Sit, Director Development | ||
| Lynn Rothman, Executive Vice President, Chief Business Officer | ||
| Arani MD, CoFounder Director | ||
| Pankaj Tiwari, Executive Officer | ||
| Harpreet Grewal, Independent Director | ||
| Maggie Yuen, Chief Financial Officer | ||
| Jee HamlynHarris, Investor Officer | ||
| Don Kassing, Presiding Independent Director | ||
| Adam JD, Chairman, CoFounder | ||
| Ben Sorci, Executive Operations | ||
| Lambert Shiu, Chief Accounting Officer | ||
| Johanna Roberts, Executive Vice President General Counsel, Secretary | ||
| MD FSIR, Chief Officer | ||
| Jason Mills, Executive Strategy | ||
| Thomas Wilder, Independent Director | ||
| Sandra Lesenfants, President Interventional | ||
| Arani Bose, Executive Director and Chief Innovator | ||
| Johanna JD, General VP | ||
| Janet Leeds, Lead Independent Director |
Penumbra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Penumbra a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.012 | ||||
| Return On Asset | 0.0484 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 10.72 B | ||||
| Shares Outstanding | 38.52 M | ||||
| Shares Owned By Insiders | 3.93 % | ||||
| Shares Owned By Institutions | 92.30 % | ||||
| Number Of Shares Shorted | 1.36 M | ||||
| Price To Earning | 191.13 X |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Penumbra. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Penumbra Stock, please use our How to Invest in Penumbra guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Penumbra. If investors know Penumbra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Penumbra listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share 0.37 | Revenue Per Share | Quarterly Revenue Growth 0.108 | Return On Assets |
The market value of Penumbra is measured differently than its book value, which is the value of Penumbra that is recorded on the company's balance sheet. Investors also form their own opinion of Penumbra's value that differs from its market value or its book value, called intrinsic value, which is Penumbra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Penumbra's market value can be influenced by many factors that don't directly affect Penumbra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Penumbra's value and its price as these two are different measures arrived at by different means. Investors typically determine if Penumbra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Penumbra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.